Z Wang, K Sun, Y Xiao, B Feng, K Mikule, XY Ma… - Scientific reports, 2019 - nature.com
PARP inhibitors have been proven clinically efficacious in platinum-responsive ovarian
cancer regardless of BRCA1/2 status and in breast cancers with germline BRCA1/2 …